Meteda
Meteda, an IQVIA business founded in 2002, develops Class IIa certified digital health software, AI screening, telemedicine, and nutrition hardware for diabetology centers, hospitals, and chronic disease management providers across Italy and Portugal.
- Company typePrivate
- Founded2002
- HeadquartersRoma, Italy
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Meteda does
Meteda S.r.l., operating as an IQVIA business since 2002, is an Italian digital health company that develops and distributes certified Class IIa medical device software and hardware for diabetes, chronic disease, and clinical nutrition management. Its core platform, MetaClinic®, is a Class IIa certified electronic medical record used by over 90% of Italian diabetology centers to manage patient follow-up, clinical documentation, complication assessments, and care pathways across multi-center deployments with unified databases. The portfolio is extended by DAIRET® (an AI deep-learning algorithm for diabetic retinopathy screening acquired via the 2022 Retmarker SA acquisition and validated on 500,000+ patients), a telemedicine suite (SmartVisit®, SmartLink®, GliConnect®) certified for Italy's Ministerial Decree 30/09/2022 telemedicine infrastructure, the MetaDieta® ecosystem (MetaDieta Studio® cloud software, MetaDieta BIA® bioimpedance hardware, MetaDieta Academy training, and MetaCare support), and Glucomagic® for glucose self-monitoring device data. All products are interoperable with Italy's Fascicolo Sanitario Elettronico (FSE 2.0), Regional Telemedicine Infrastructures, and Local Health Authorities.
The company monetizes primarily through enterprise license sales (sold as annual subscriptions to healthcare institutions), hardware device sales (MetaDieta BIA®, telemedicine kits), and recurring support and training services (MetaCare, MetaDieta Academy). Go-to-market is sales-led, with a direct sales team ([email protected]) and field engagement at events like the AMD National Congress targeting diabetology centers, hospitals, and chronic disease management facilities, supplemented by referral networks through IQVIA and the AMD scientific society. Customers are concentrated in Italy, with secondary operations in Portugal (via Retmarker SA) and international expansion signaled through participation in EU-funded research consortia (DigiCare4You, MindLink, CRANE, CORRAL). Multiple ISO certifications (9001, 13485, 27001 with 27017/27018) and UNI/PdR 125:2022 gender equality certification underpin institutional procurement eligibility.
Meteda firmographics
Firmographics- Name
- Meteda
- Legal name
- METEDA S.r.l.
- Website
- https://meteda.it
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Meteda, an IQVIA business founded in 2002, develops Class IIa certified digital health software, AI screening, telemedicine, and nutrition hardware for diabetology centers, hospitals, and chronic disease management providers across Italy and Portugal.
- Ownership category
- akta.pro rank
Meteda industry classification
Industry- Product category
- Digital Health Software for Diabetes and Chronic Disease Management
- NAICS
- Software Publishers (5132), Surgical Appliance and Supplies Manufacturing (339113), Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management) (HLALAFAL)
- akta.pro secondary industries
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration) (HLACAPAJ), Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)
Keywords
Where Meteda is headquartered
LocationHeadquarters
- HQ city
- Roma
- HQ country
- Italy
- HQ region
- Europe
Offices4 records
Markets served
Meteda business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Software Licenses: Sale of certified medical device software (Class IIa) to healthcare institutions including diabetology centers, hospitals, and chronic disease management facilities. Sold as licensed software with ongoing support and updates.
- Hardware Devices: Sale of certified medical hardware including MetaDieta BIA® portable bioimpedance analyzers, glucose monitoring integration devices, and telemedicine equipment.
- Support and Training Services: MetaCare support services and MetaDieta Academy training programs provided to healthcare professionals and institutions using Meteda platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise healthcare institution licensing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Meteda product offering
Product offeringCore offering
Meteda develops and distributes certified Class IIa medical device software and hardware for diabetes and chronic disease management. Its core product, MetaClinic®, is a digital electronic medical record used in over 90% of Italian diabetology centers, supported by telemedicine devices (SmartVisit®, SmartLink®, GliConnect®), a nutrition ecosystem (MetaDieta®), and AI-powered screening tools (DAIRET®). Solutions are sold as annual software subscriptions and hardware to healthcare institutions, hospitals, and chronic disease management facilities.
Product overview
Meteda develops a comprehensive digital health ecosystem comprising multiple integrated products: MetaClinic® (Class IIa certified electronic medical record for diabetology and chronic diseases, deployed in over 90% of Italian diabetes centers), telemedicine modules (SmartVisit® for televisits, SmartLink® for secure messaging, GliConnect® for glucose telemonitoring), MetaDieta® ecosystem (MetaDieta Studio® cloud platform, MetaDieta BIA® bioimpedance device, MetaCare support services, MetaDieta Academy training), Glucomagic® glucose monitoring software, and AI-powered DAIRET® for diabetic retinopathy screening. The company operates as an IQVIA business focused on chronic disease management solutions.
Differentiator
Problem solved
Functional benefit
Brands
- MetaClinic: Class IIa certified electronic medical record for diabetology and chronic disease management, used in over 90% of Italian diabetology centers
- MetaDieta
- SmartVisit
- SmartLink
- GliConnect
- DAIRET
- Retmarker
Products and services
- MetaClinic®
Quantifiable outcome
- Used in over 90% of Italian diabetology centers
- +3 more outcomes
Companies that use Meteda
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Meteda technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability5 records
Feature6 records
Meteda partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core, major and strategic.
- Retmarker SAcoreMeteda acquired Portuguese AI company Retmarker SA in January 2022 to enhance diabetic retinopathy screening solutions. Retmarker developed the AI algorithm Screening DR, used on over 500,000 patients and validated in international scientific publications. The technology is now integrated as DAIRET® in MetaClinic®.
- Associazione Medici Diabetologi (AMD)majorAMD is the Italian Association of Diabetologists. MetaClinic® is recognized by AMD as a proven tool supporting nationwide diabetes care and management. The collaboration enables publication of AMD Annals, a key survey on Italian diabetology based on data collected through MetaClinic®.
- European Research Consortium PartnersstrategicMeteda participates in European research projects including DigiCare4You (2021-2026), MindLink, CRANE (Pre-Commercial Procurement), and Corral, collaborating with universities, research centers, and international industrial partners to develop and test new models of care based on data, AI, interoperability, and personalized medicine.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Meteda competitors and assessment
Company assessmentBroad incumbents
- Dexcom: Global continuous glucose monitoring leader whose Clarity software overlaps with Glucomagic®; broad incumbent adjacent to Meteda's glucose telemonitoring module GliConnect®.
- Dedalus Group: Major European healthcare IT vendor offering hospital EHRs and diagnostic modules across Italy; broad incumbent competing with MetaClinic® at the hospital-procurement level.
- Medtronic Diabetes: Global incumbent in insulin pumps, CGM systems, and diabetes decision-support software; competes with Meteda's diabetes management and telemonitoring stack.
Direct peers
- mySugr (Roche): Diabetes management app and platform owned by Roche; directly competes with MetaClinic® in digital diabetes diaries, glucose tracking, and clinician-facing tools.
- Glooko: Device-agnostic diabetes data management platform aggregating data from glucometers, insulin pumps, and CGMs; comparable to Glucomagic® and MetaClinic® in data aggregation across diabetes devices.
- DarioHealth: Public digital therapeutics company focused on diabetes and chronic-condition management; competes with Meteda in chronic care platforms and AI-driven patient coaching.
- Vivify Health: Remote patient monitoring and chronic care management platform for health plans and providers; comparable to GliConnect®-style RPM combined with EMR integration.
Emerging players
- Luscii: European platform for remote patient monitoring and virtual care, including chronic-condition programs; comparable to SmartVisit®, SmartLink®, and GliConnect® telemedicine devices.
- Tidepool: Nonprofit diabetes data platform with strong clinician and patient tooling for diabetes device data; comparable as an interoperable, multi-condition diabetes data ecosystem.
- Voluntis (AptarGroup): Digital therapeutics company historically focused on insulin titration in diabetes; highly comparable to MetaClinic's AI-driven decision support and predictive complication features.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Meteda social profiles
Digital presenceMeteda compliance and trust
Trust signalCompliance7 records
Meteda financial estimates
Financial estimateRevenue estimate
Valuation estimate
Meteda leadership team
Management profileNumber of profiles
Profiles1 record
Meteda subsidiaries and ownership
Company hierarchySubsidiaries1 record
Meteda funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Meteda M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Meteda
What does Meteda do?
Meteda develops and distributes certified Class IIa medical device software and hardware for diabetes and chronic disease management. Its core product, MetaClinic®, is a digital electronic medical record used in over 90% of Italian diabetology centers, supported by telemedicine devices (SmartVisit®, SmartLink®, GliConnect®), a nutrition ecosystem (MetaDieta®), and AI-powered screening tools (DAIRET®). Solutions are sold as annual software subscriptions and hardware to healthcare institutions, hospitals, and chronic disease management facilities.
Is Meteda a public or private company?
Meteda is a private company. It is classified as corporate owned and is currently operating.
When was Meteda founded?
Meteda was founded in 2002. It employs 11 to 50 people.
Where is Meteda based?
Meteda is headquartered in Roma, Italy, in the Europe region.
How does Meteda make money?
Three revenue lines are on record. Medical Software Licenses are the primary driver. The others are hardware Devices and support and Training Services.
Who are Meteda's main competitors?
Broad incumbents on record are Dexcom, Dedalus Group and Medtronic Diabetes. Direct peers are mySugr (Roche), Glooko, DarioHealth and Vivify Health. Emerging players are Luscii, Tidepool and Voluntis (AptarGroup).
Does Meteda have an API?
No public API is recorded for Meteda.
What industry is Meteda in?
Meteda's product category is Digital Health Software for Diabetes and Chronic Disease Management. Its primary akta.pro industry code is HLALAFAL, Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 5132 and its SIC code is 7372.